Photo: partnering meetings at BIO 2018.
6th, June 2018
PROALT has participated in the partnering event at BIO International Convention in Boston, MA (USA), to present the latest advances of COLODETECT, the non-invasive test in development by the company that will allow early detection of colorectal cancer (CCR) in patients affected by this disease, even when clinical symptoms are still not visible. The test will initiate soon the clinical validation process, with the focus on launching the product on the market after obtaining the CE mark (IVD). Initially it is planned to be marketed in Europe, and later in the United States, Australia and Canada.
On the therapeutic area, PROALT is advancing the preclinical phase of its therapeutic program with monoclonal antibodies for the treatment of colorectal, breast and melanoma metastatic tumors.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.